Alzheimer’s progression slowed by drug in major trial
Though the effect of Eisai and Biogen’s treatment was small, and reported side effects were serious, this is the first large clinical trial in which cognitive decline caused by Alzheimer’s has been delayed.
By Robert Langreth and Michelle Fay Cortez, bloomberg
Eisai Co. and partner Biogen Inc. said their drug significantly slowed Alzheimer’s disease, making it the first medicine to blunt progression of the most common dementia in a definitive, large-scale trial.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.